Vietnam Diabetes Care Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The report covers Diabetes Care Drugs in Vietnam and is segmented by drugs (oral anti-diabetic drugs, insulin, non-insulin injectable drugs, and combination drugs).

Vietnam Diabetes Care Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Vietnam Diabetes Care Drugs Industry Overview

The Vietnam diabetes drugs market is moderately fragmented, with few significant and generic players. The insulin and Sglt-2 drug markets are dominated by a few major players, like Novo Nordisk, Sanofi, AstraZeneca, and Bristol-Myers Squibb. The market for oral drugs like sulfonylureas and meglitinides comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, to increase their market shares, players are tapping into new markets, especially emerging economies where the demand is very high compared to the supply.

Vietnam Diabetes Care Drugs Market Leaders

  1. Eli Lilly

  2. Boehringer Ingelheim

  3. Astrazeneca

  4. Sanofi

  5. NovoNordisk

  6. *Disclaimer: Major Players sorted in no particular order
Vietnam Diabetes Care Drugs Market Concentration